The historical rank and industry rank for Instituto Rosenbusch's Pretax Margin % or its related term are showing as below:
BUE:ROSE'
s Pretax Margin % Range Over the Past 10 Years
Min: -69.7 Med: -0.87 Max: 13.91
Current: -69.7
BUE:ROSE's Pretax Margin % is ranked worse than 88.99% of 954
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs BUE:ROSE: -69.70
Instituto Rosenbusch (BUE:ROSE) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Instituto Rosenbusch Pretax Margin % Related Terms
Instituto Rosenbusch Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Instituto Rosenbusch's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUE:ROSE vs ZTS, UTHR, VTRS: Pretax Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instituto Rosenbusch Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Instituto Rosenbusch's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instituto Rosenbusch (BUE:ROSE) has a Pretax Margin % of -60.14% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Instituto Rosenbusch and its competitors. According to the industry distribution chart, Instituto Rosenbusch ranks #849 out of 954 companies in the Drug Manufacturers industry, placing it in the top 89%.
Is Instituto Rosenbusch's Pretax Margin % too high?
Instituto Rosenbusch's current Pretax Margin % is -60.14%. Based on the distribution chart, Instituto Rosenbusch ranks #849 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Instituto Rosenbusch has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Pretax Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Instituto Rosenbusch ranks #849 out of 954 companies for Pretax Margin %. This places Instituto Rosenbusch in the lower half of its industry. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Instituto Rosenbusch and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Instituto Rosenbusch's current Pretax Margin % is -60.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.86, compared to a current price of ARS163.00 — trading 163.5% above its estimated fair value. The current Pretax Margin % is -60.14%. Instituto Rosenbusch's overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Pretax Margin % is -60.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?
Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued.
The current stock price of ARS163.00 is trading 163.5% above its estimated GF Value™ of ARS61.86.
GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.
Key valuation signals for BUE:ROSE:
Pretax Margin %: -60.14%
GF Value™: ARS61.86 vs. price of ARS163.00 (163.5% above fair value)
No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
37GF Score
Get the complete analysis for BUE:ROSE
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUE:ROSE has been successfully added to your 
